A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php5/sessions/ci_session68b0bc33081fdff041715bc7bf074c066ebf3cee): failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 156

Backtrace:

File: /var/www/tradedeals.biz/cdi/application/libraries/Ion_auth.php
Line: 67
Function: library

File: /var/www/tradedeals.biz/cdi/application/controllers/Product.php
Line: 6
Function: __construct

File: /var/www/tradedeals.biz/index.php
Line: 292
Function: require_once

Vandetanib/ 4-quinazolinamine/zactima/zd 6474 Cas 110958-19-5 for Cancer Treatment  (jerryzhang001 - Nanjing Bangnuo Biotechnology Co., Ltd.

Vandetanib/ 4-quinazolinamine/zactima/zd 6474 Cas 110958-19-5 for Cancer Treatment  (jerryzhang001

PRICE: 5 USD
Product Description

Oral Safe and Super Pure 99% Vandetanib/ 4-Quinazolinamine/Zactima/ZD 6474

CAS 110958-19-5 for Cancer Treatment 

 

  1. Quick Detail:

 

Name: Vandetanib

Other Name: 4-Quinazolinamine;Zactima;ZD 6474

Purity : 99%

CAS : 443913-73-3

MF: C22H24BrFN4O2

MW: 475.35

Appearance: Yellow Powder

Place of Origin:  China

Brand Name: NJBNSteroid

Usage: Vandetanib (Zactima, ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM and  is used as anticancer drug material.

 

  1. Features of Vandetanib :

Vandetanib is a kind of small molecule multi-targeted tyrosine kinase inhibitor studied and developed by the British AstraZeneca Company. In April 2011, it was approved the US FDA for entering into market under the trade name Zactima. The drug, as a tablet, can be applied to the treatment of advanced medullary thyroid cancer of adult patients. 

 3.Clinical Conclusion

A clinical trial conducted by doctors Ronald B. Natale from Los Angeles Cedars-Sinai Cancer Center, clinical study compared the treatment efficacy of vandetanib (300 mg/d) and gefitinib (250mg/d) on 168 cases of NSCLC patients who had been subject to failing first-line or second-line chemotherapy. Compared with gefitinib, vandetanib significantly increased efficiency and prolonged the progression-free survival, period respectively, by 8% and 1%, 11.9 weeks and 8.1 weeks, (P = 0.011).


Other products

Company Info

Nanjing Bangnuo Biotechnology Co., Ltd.
Contact Person:
Jerry Zhang
Phone:
86-25-52198306

0.0181:0.95MB

A PHP Error was encountered

Severity: Warning

Message: rewind() expects parameter 1 to be resource, boolean given

Filename: drivers/Session_files_driver.php

Line Number: 188

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: filesize(): stat failed for /var/lib/php5/sessions/ci_session68b0bc33081fdff041715bc7bf074c066ebf3cee

Filename: drivers/Session_files_driver.php

Line Number: 192

Backtrace: